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A prospective study of false-positive cultures of Mycobacterium tuberculosis that resulted from laboratory
cross-contamination was conducted at three laboratories in California. Laboratory cross-contamination
accounted for 2% of the positive cultures. Cross-contamination should be a concern when an isolate
matches the genotype of another sample processed during the same period. 
ulture remains the reference standard for diagnosis of dis-
ease caused by Mycobacterium tuberculosis. However,
false-positive results can be caused by cross-contamination of
cultures in the laboratory, e.g., when M. tuberculosis bacilli are
transferred from one specimen to another specimen that does
not contain viable bacilli (1–10). Historically, determining
whether false-positive results are caused by laboratory cross-
contamination has been difficult because of the lack of specific
strain identification and nonsystematic criteria. False-positive
cultures for M. tuberculosis have important implications for
clinical management of patients. Many patients are treated on
the basis of the results; therefore, patients can be exposed to
unnecessary, potentially toxic, and costly treatment. Genotyp-
ing of M. tuberculosis strains has become the standard method
for determining whether isolates are clonal (11–14). This tech-
nique, in combination with a review of clinical and radio-
graphic data, allows a determination of the incidence of
laboratory cross-contamination of M. tuberculosis cultures. In
this study, we used predefined criteria to investigate possible
laboratory cross-contamination of M. tuberculosis cultures and
prospectively determine its incidence in an effort to find meth-
ods to decrease the occurrence of cross-contamination.
Methods
Study Laboratories and Patients
This study was conducted by staff of the Microbial Dis-
eases Laboratory, California Department of Health Services,
Berkeley, California, which is one of seven participants in the
National Tuberculosis Genotyping and Surveillance Network
of the Centers for Disease Control and Prevention. Participat-
ing California laboratories included those at the San Francisco
General Hospital, Santa Clara Valley Medical Center (San
Jose), and Solano County Public Health Laboratory (Vallejo).
The study was conducted from January 1, 1998, to June 30,
1999. 
Laboratory Methods
M. tuberculosis isolates from all sources underwent
IS6110-based DNA restriction fragment length polymorphism
(RFLP) analysis (11) if they were 1) the patient’s first M.
tuberculosis–positive culture derived from a sample cultured
in the participating laboratory; 2) cultured from a specimen
collected >30 days after an M. tuberculosis culture–negative
specimen was obtained; or 3) cultured from a specimen col-
lected >90 days after the start of appropriate anti-tuberculosis
(TB) therapy. When five or fewer bands were present, the iso-
lates underwent secondary genotyping with a RFLP analysis
based on a polymorphic GC-rich sequence (12–14).
RFLP pattern images were entered into a database and
compared to identify isolates with matching genotypes. Any of
the following cultures were considered potentially cross-con-
taminated and underwent further investigation: 1) the first M.
tuberculosis–positive culture for a patient whose isolate had a
genotype that matched that of another isolate cultured or used
in the participating laboratory 2 days before or after the poten-
tially cross-contaminated culture; 2) an M. tuberculosis culture
from a specimen obtained >30 days after the collection of an
M. tuberculosis culture-negative specimen that had an isolate
with a genotype different from that of any previous isolate
from the same patient; or 3) an M. tuberculosis culture, from a
specimen collected >90 days after the start of appropriate anti-
TB therapy, in which the isolate had a genotype different from
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that of any previous isolate from the same patient. 
Patients with specimens meeting the above criteria and for
whom potential source isolates were identified (i.e., their iso-
lates had a genotype that matched that of a potential source
isolate) underwent further investigation. The investigation
included a review of all clinical data and radiologic studies, if
applicable, and possible epidemiologic connections between
patients with potential source and contaminated specimens.
Clinical data included prior history of TB, results of tuberculin
skin tests, treatment of latent TB infection, symptoms of
present illness, results of diagnostic evaluations for TB, and
alternative diagnoses. Personnel in laboratories where the
potentially cross-contaminated specimens were processed also
investigated potential sources of cross-contamination within
their facilities. 
Determination of Cross-Contamination
A final determination of laboratory cross-contamination
was made after a panel of experts reviewed each case. The
panel comprised three genotyping network investigators from
sites other than California. Panel members met once at the
conclusion of the study and reviewed all information from lab-
oratory and medical records, epidemiologic investigations, and
genotyping images (upon request). Cases were presented to the
panel members in person by one of the authors (RJ). Panel
members independently recorded their conclusions on whether
cross-contamination was likely, as well as their final diagnosis,
and submitted these results to the senior investigator of the
study (ED). 
Results
Review showed that similar methods for specimen pro-
cessing were used in all three participating laboratories. How-
ever, one laboratory used a common flask for dispensing
decontaminant reagent and phosphate buffer rather than an
individual tube or pipette for each specimen.
During the study period, 21,835 specimens were submitted
for mycobacterial culturing at the three laboratories. Of these,
988 (4.5%) from 296 different patients were positive for M.
tuberculosis. Twenty-seven had only a single positive culture.
Of these, specimens from 10 patients met criteria for an inves-
tigation of possible laboratory cross-contamination (Table). 
After the panel’s review, laboratory cross-contamination
was identified as the cause for positive culture results for six
patients (2% of all patients with cultures positive for M. tuber-
culosis) (Table). Rates were similar at two of the three labora-
tories, ranging from 2.8% in both Laboratories 1 (1 of 36
patients) and 2 (5 of 179 patients) to 0% (0 of 81 patients) with
a culture positive for M. tuberculosis in Laboratory 3. At Lab-
oratory 2, a common flask was used for dispensing reagents
during the study period. One of the cross-contamination inci-
dents (involving Patient 4) probably resulted from a malfunc-
tioning broth-culturing system (BACTEC 460) (Becton
Dickinson Microbiology Systems, Sparks MD). Patient 4’s
specimen was in the BACTEC instrument immediately after
another patient’s specimen (not processed on the same day),
and genotypes of the two isolates matched. Cultures from two
patients (Patients 7 and 9) were cross-contaminated from the
same source patient during sample processing. All six of the
laboratory cross-contamination incidents occurred with the
initial rather than follow-up specimens for mycobacterial cul-
ture. Five of these six patients were treated for TB. Of the
remaining four patients whose isolates were suspected of
being cross-contaminated in the laboratory, one had a false-
positive culture attributed to specimen mislabeling by a health-
care provider; one had either a mislabeled specimen or mixed
infection; one had active TB; and one had either a mislabeled
specimen or a cross-contaminated specimen (Table). Having
only a single positive culture was highly associated with labo-
ratory cross-contamination (p<0.001, Fisher exact test).
Discussion
Laboratory cross-contamination was the cause for a posi-
tive culture result in 2% of all patients with M. tuberculosis–
positive cultures. Cross-contamination accounted for one fifth
(22%) of patients having only one culture positive for M.
tuberculosis. Of the six patients who had cross-contaminated
cultures, five were treated unnecessarily with multiple anti-TB
medications.
The rate of cross-contaminated cultures in our study is
similar to the rates in previous studies of M. tuberculosis cul-
tures. Most population-based studies found rates of 0.9% to
3.5% (1–8). However, such studies were retrospective and did
not assess the extent of the problem in different types of clini-
cal mycobacteriology laboratories. In this study, we used pre-
defined criteria, which were based largely on DNA
genotyping, to identify suspected cases of laboratory cross-
contamination prospectively in an effort to correct factors
associated with its occurrence. Our study included all clinical
specimens submitted during a 1.5-year period to one county
public health laboratory and two county hospital laboratories.
This study was possible because of the large databank of
RFLP results conducted as part of being a member of the
genotyping network.
Multiple factors can cause false-positive cultures, includ-
ing contaminated clinical equipment (e.g., bronchoscope),
clerical errors, and cross-contamination that occurs in the labo-
ratory. The last category can be caused by batch processing,
transfer of viable bacilli from the sample needle of a broth-cul-
turing system, e.g., BACTEC (15), a faulty exhaust hood (4),
and contamination from species identification procedures such
as the niacin production test (6). 
Five of the six cross-contamination incidents were in a sin-
gle laboratory. In four of these five cases, contamination prob-
ably occurred when reagents were dispensed with a common
flask. Previous studies have reported that the step of adding
the phosphate buffer was likely to have been the source of the
cross-contamination (1,6,9). This procedure was later discon-
tinued on the basis of the results of this study. None of the lab-
oratories used positive control cultures.TUBERCULOSIS GENOTYPING NETWORK
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As in other studies, we found that a single positive culture
for M. tuberculosis was a sensitive but nonspecific marker for
detection of a false-positive culture, since most patients (78%)
with a single positive culture had TB. In a New York study (7),
12 (44.4%) of 27 patients with a single positive culture had a
false-positive culture. These findings suggest that clinicians
and laboratorians should be increasingly suspicious of a single
false-positive culture.  Additional specimens should be col-
lected in cases of a single false-positive culture and the patient
evaluated carefully for TB and other illnesses; the laboratory
Table. Clinical and laboratory characteristics of patients suspected of having false-positive cultures for Mycobacterium tuberculosisa
Patient Lab
Specimen 
type
Initial or 
follow-up 
specimen
Sputum 
smear result Clinical signs and symptoms Comments Panel decision Final diagnosis
1 1 Sputum Initial Negative 36-yr-old man with AIDS 
hospitalized with cough, 
dyspnea, right lower lobe 
infiltrate; he improved with 
trimethoprim and sul-
famethoxazole alone
Genotype of isolate 
matched that of another 
patient whose specimen 
was processed same day
Cross-contamination Bacterial 
pneumonia
2 2 Sputum Initial 2+ Positive 28-yr-old man with HIV 
infection with fever, cough, 
right lower lobe infiltrate; 
improved with ceftazidime
Genotype of isolate 
matched that of another 
patient hospitalized on 
the same ward
Mislabeled 
specimen
Bacterial 
pneumonia
3 2 Sputum Initial Negative 31-yr-old woman hospital-
ized with cough, left lower 
lobe infiltrate, and leukocy-
tosis; chest radiograph 
showed improvement with 
clindamycin and ofloxacin
Genotype of isolate 
matched that of another 
patient whose specimen 
was processed same day
Cross-contamination Bacterial 
pneumonia
4 2 Sputum Initial Negative 44-yr-old man hospitalized 
with cough and right lower 
lobe infiltrate; improved 
with levofloxacin before 
anti-TB therapy initiated
Genotype of isolate 
matched that of another 
patient whose specimen 
in the BACTEC instru-
ment immediately pre-
ceded the case patient
Cross-contamination Lung abscess
5 2 Sputum Follow-up Negative 68-yr-old woman newly 
immigrated from China with 
cough; chest radiograph 
showed bi-apical fibronodu-
lar changes 
Genotype of second iso-
late >30 days later did not 
match that of initial iso-
late or any other isolate in 
database
Mislabeled 
specimen or mixed 
infection
Bacterial 
pneumonia versus 
TB with mixed 
infection
6 2 Sputum Initial 4+ Positive 82-yr-old man with cough, 
fever; chest radiograph 
showed chronically 
increased right mid-lung 
interstitial markings
Genotype of isolate 
matched that of another 
patient hospitalized on 
the same ward
Mislabeled 
specimen or cross-
contamination
Bacterial 
pneumonia
7 2 Sputum Initial Negative 27-yr-old woman with upper 
respiratory symptoms; chest 
radiograph was normal
Genotype of isolate 
matched that of another 
patient whose specimen 
was processed same day
Cross-contamination Upper respiratory 
tract infection 
8 2 Sputum Initial Negative 44-yr-old man with hemop-
tysis and known pulmonary 
metastases of squamous cell 
carcinoma of trachea; chest 
radiograph showed three 
large cavities with air-fluid 
levels; bronchoscopy culture 
grew H. influenzae, and 
patient improved on antibi-
otics alone
Genotype of isolate 
matched that of another 
patient whose specimen 
was processed same day
Cross-contamination Lung abscess
9 2 Broncho-
alveloar 
lavage
Initial Negative 55-yr-old woman hospital-
ized with dyspnea and left 
lower lobe infiltrate; she 
improved with broad-spec-
trum antibiotics alone
Genotype of isolate 
matched that of another 
patient whose specimen 
was processed same day
Cross-contamination Bacterial 
pneumonia
10 3 Sputum Follow-up Negative 34-yr-old homeless man 
with HIV infection, fever, 
and cervical lymphadenopa-
thy; chest radiograph 
showed left lung nodule
Genotype of initial isolate 
matched that of another 
homeless TB patient; fol-
low-up specimen (35 
days later) had a unique 
genotype
TB TB
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should also retain the isolate and others processed that day for
genotyping. Because all specimens that met the inclusion cri-
teria in our study were from the respiratory tract, we cannot
draw any conclusions about the rate of cross-contamination of
nonrespiratory specimens (e.g., cerebrospinal or pleural fluid).
Nor can we draw any conclusions about a single positive cul-
ture when only a single specimen is submitted to the labora-
tory, as is often the case with nonrespiratory specimens.
Clinical judgment is also important in raising suspicion
about cross-contamination. TB classically is accompanied by
symptoms of prolonged cough, fever, weight loss, and night
sweats, but other diseases such as bacterial pneumonia can
cause these symptoms. Therefore, no specific clinical criterion
alone can be used to definitively state that TB is present. How-
ever, an inconsistent clinical course or absence of symptoms
should certainly raise suspicion that cross-contamination may
have occurred (3,8,16). A determination regarding the pres-
ence of cross-contamination requires a thorough evaluation of
a patient’s symptoms and clinical course as well as laboratory
evaluation, with additional specimens obtained if only a single
culture is positive as described above. Genotyping should be
performed if cross-contamination is suspected on the basis of
an inconsistent clinical course or the presence of only one pos-
itive culture (8).
Our assessment of the rate of cross-contamination did not
include private laboratories; thus, our results may not be gen-
eralizable to all types of clinical laboratories. In addition, our
methods depended on identifying, obtaining, and genotyping
an isolate from a positive source culture; thus, we may have
underestimated the true rate of laboratory cross-contamination. 
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